Scarica l'app Stockscreener
100.35
1.28%
1.27
Dopo l'orario di chiusura:
100.90
0.55
+0.55%
Celcuity Inc Borsa (CELC) Ultime notizie
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
(CELC) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Celcuity Inc. stock reacts to job market dataJuly 2025 Macro Moves & Free Community Consensus Stock Picks - BỘ NỘI VỤ
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference - The Manila Times
Celcuity Inc. to Participate in 8th Annual Evercore Healthcare Conference with CEO Fireside Chat Scheduled for December 3, 2025 - Quiver Quantitative
Celcuity Inc. (CELC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data - Investing.com India
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data By Investing.com - Investing.com South Africa
What analysts say about Celcuity Inc stockMarket Sentiment Indicators & Learn to Trade Without Fear of Loss - earlytimes.in
Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View - Finviz
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - Insider Monkey
Celcuity (CELC) Price Target Increased by 16.06% to 97.66 - MSN
Celcuity Director Unloads Shares in a Major Stock Sale! - TipRanks
Celcuity Insider Sold Shares Worth $377,255, According to a Recent SEC Filing - MarketScreener
Dir Buller Sells 3,900 ($377.3K) Of Celcuity Inc [CELC] - TradingView
Dir Dalvey Files To Sell 15,000 Of Celcuity Inc [CELC] - TradingView
Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer TherapyHas The Bull Case Changed? - simplywall.st
Why Celcuity Inc. stock is popular among millennials2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Celcuity initiated with an Outperform at Wolfe Research - MSN
Celcuity submits gedatolisib new drug application to the FDA - MSN
Celcuity Inc. (CELC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celcuity stock reaches all-time high of 96.56 USD By Investing.com - Investing.com Canada
How institutional buying supports Celcuity Inc. stock2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stock2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Price action breakdown for Celcuity Inc.July 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Wolfe Research Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - MSN
Key resistance and support levels for Celcuity Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited ReviewWhat's Changed - Yahoo Finance
When is the best time to exit Celcuity Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
How to track smart money flows in Celcuity Inc.July 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating By Investing.com - Investing.com South Africa
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating - Investing.com India
Celcuity Submits NDA for Gedatolisib to FDA - TipRanks
Celcuity Inc Submits NDA for Gedatolisib to FDA - TradingView
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer - MarketScreener
Celcuity Inc. Submits New Drug Application for Gedatolisib to Treat Advanced Breast Cancer - Quiver Quantitative
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - The Manila Times
Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan
Celcuity Shares Fall After HC Wainwright Downgrade - MarketScreener
Celcuity dips as H.C. Wainwright downgrades to 'neutral' - TradingView
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy ApplicationCelcuity (NASDAQ:CELC) - Benzinga
HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77 - MarketScreener
HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94 - MarketScreener
Liquidity Mapping Around (CELC) Price Events - news.stocktradersdaily.com
0.76%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):